6.Do K, Doroshow JH, Kummar S. Wee1 kinase as atarget for cancer therapy. Cell Cycle. 2013 Oct 1;12(19):3159-64. doi:10.4161/cc.26062. Epub 2013 Aug 26. PMID: 24013427; PMCID: PMC3865011. 7.Moiseeva TN, Qian C, Sugitani N, Osmanbeyoglu HU,Bakkenist CJ. WEE1 kinase inhibit...
Shivaani KummarDo K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12: 3159-3164.Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12:3159-64; PMID: 24013427; http://dx.doi.org/10.4161/cc.26062...
Zhang等[16]还证实了Wee1在胃癌细胞中的表达增加,罗哌卡因(ropivacaine,Rop)通过上调miR-520a-3p基因的表达使Wee1和磷脂酰肌醇-3-激酶(phosphatidylinositol 3-kinase,PI3K)/蛋白激酶B(protein kinase B,PKB,又称AKT)失活最终抑制GC中肿瘤细胞...
10、Do K, DoroshowJH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell cycle. 2013 Oct1;12(19):3348-53. 11、Ashwell S.Checkpoint kinase and Wee1 inhibitors as anticancer therapeutics. InDNA repairin cancer therapy 2012 Jan...
Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12: 3159–3164. 18. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019–5032. 19...
Wee1 kinase as a target for cancer therapy. Cell Cycle 12, 3348–3353 (2013). Article CAS Google Scholar Schwob, E. The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae. Cell 79, 233–244 (1994). Article CAS PubMed Google Scholar Verma, R...
Drug resistance to EGFR inhibitors in lung Cancer Chemotherapy, 61 (5) (2016), pp. 223-235 CrossrefView in ScopusGoogle Scholar [13] K. Do, J.H. Doroshow, S. Kummar Wee1 kinase as a target for cancer therapy Cell Cycle, 12 (19) (2013), pp. 3159-3164 Google Scholar [14] J....
Wee1 kinase as a target for cancer therapy Wee1, a protein kinase, regulates the G2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair an... S Mueller,DA Haas-Kogan - 《Journal of Clinical Oncology Official Journal of the Ameri...
WEE1 kinase, a promising target for cancer therapy, is crucial for S and G2 phase cell cycle checkpoint arrest. WEE1 inhibits CDK1 activity, preventing DNA-damaged cells from entering mitosis. G1/S phase checkpoint inactivation is common in patient with OC due to p53 mutations. WEE1 ...
The specificity of Wee1 as the target of MK-1775 was validated by Wee1 knockdown, as well as partial reversal of drug combination-induced apoptosis by a cyclin-dependent kinase 1 (CDK1) inhibitor. Importantly, we also extended our findings to other mutant RAS-expressing malignancies, including...